Remote Patient Monitoring 65% Revenue Cut After CMS Ban
— 5 min read
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.
What the CMS third-party vendor ban means for RPM
CMS’s proposal to end Medicare payment for outsourced remote monitoring could cut RPM providers' revenue by as much as 65%, according to industry surveys. In practice, the rule would force many healthtech firms to either bring device management in-house or exit the Medicare market entirely. This shift threatens the supply chain that underpins chronic-care monitoring across Australia and the United States.
Look, here's the thing: the ban is not just a paperwork tweak. It targets the very model that has allowed small firms to scale quickly by partnering with third-party vendors for device provisioning, data aggregation, and billing. When those relationships disappear, the cost base rises sharply and the speed of patient onboarding slows to a crawl.
In my experience around the country, I’ve seen this play out when regulatory changes forced a regional telehealth provider in Queensland to re-engineer its back-end in under six months. The lesson is clear - preparation now will avoid a scramble later.
Key Takeaways
- CMS ban could cut RPM revenue by up to 65%.
- Third-party vendor reliance is the biggest risk.
- Three moves can future-proof your service.
- In-house solutions raise costs but improve control.
- Regulatory compliance must start today.
Three critical moves to keep your RPM services uninterrupted
When a regulatory shock hits, you need a playbook. I’ve broken down the response into three practical steps that any RPM provider can start this week.
- Audit your current vendor contracts. Pull every agreement that touches device supply, data transmission, or billing. Note the termination clauses, data-ownership terms, and any clauses that reference CMS rules. This audit will tell you where the exposure lies.
- Build an in-house capability roadmap. Identify which functions you can realistically internalise - for most firms that means device provisioning and data aggregation. Use a phased approach: pilot a small patient cohort, then scale.
- Phase 1 - technology selection (hardware, cloud platform).
- Phase 2 - staff training and SOP development.
- Phase 3 - full-scale rollout and de-risking of third-party ties.
- Engage with regulators early. Submit a formal comment on the CMS proposal and request a meeting. Demonstrating proactive compliance can earn you a grace period or a pilot exemption. In the United States, firms that lodged early comments were granted up to six months extra to transition.
These moves are not optional if you want to keep serving Medicare patients without a massive revenue hit. The steps also align with the broader goal of improving data security - a benefit that patients and clinicians alike appreciate.
Building a resilient supply chain for remote monitoring devices
Supply-chain resilience is the backbone of any RPM operation. After the CMS ban, the old model of "buy-and-forget" third-party devices will no longer work. Below is a quick comparison of two approaches.
| Aspect | In-house Management | Third-party Vendor |
|---|---|---|
| Initial Capital Outlay | High - equipment purchase, IT infrastructure | Low - pay-per-device or subscription |
| Regulatory Control | Full - you set compliance standards | Limited - vendor dictates terms |
| Scalability | Moderate - requires internal staffing | High - vendor scales for you |
| Data Security | Customisable security protocols | Vendor-dependent security |
| Cost Over Time | Decreases as volume grows | Variable - often increases with volume |
According to Fast Company the RPM market is poised to become a multi-billion-dollar sector, but that growth only materialises if providers can secure a reliable hardware pipeline.
Practical steps to tighten your supply chain:
- Diversify manufacturers. Don’t rely on a single OEM for wearables; qualify at least two alternatives.
- Standardise data protocols. Use HL7 or FHIR standards so switching hardware doesn’t break integration.
- Maintain a buffer stock. Keep a 3-month inventory of critical devices to hedge against shipping delays.
- Negotiate long-term service contracts. Lock in service-level agreements that include firmware updates and device-retirement plans.
Compliance strategy and timeline for the new CMS rules
Compliance is not a one-off checkbox; it’s a timeline of actions that must align with the CMS proposal release date (expected Q4 2024). Below is a month-by-month guide that I have used with several healthtech start-ups.
- Month 1-2: Gap analysis. Map every process that touches Medicare billing and identify which are tied to third-party vendors.
- Month 3-4: Policy drafting. Write internal policies that meet the new CMS definitions of “direct provision”. Include consent forms, data-ownership clauses, and device-maintenance SOPs.
- Month 5-6: Technology upgrade. Deploy a cloud-based data lake that can ingest raw device data without vendor middleware. Ensure it complies with HIPAA and Australian Privacy Act.
- Month 7-8: Staff certification. Run a mandatory training module for clinicians, coders, and tech staff on the new billing pathways.
- Month 9: Pilot launch. Run a small-scale pilot with 50 Medicare patients using the in-house workflow. Capture metrics on enrollment time, claim denial rate, and patient satisfaction.
- Month 10-12: Full rollout and monitoring. Expand to the full patient base, continuously audit claim submissions, and adjust SOPs as needed.
Throughout this timeline, keep a compliance log - a simple spreadsheet that records every change, the person responsible, and the date. This log will be your evidence if CMS asks for proof of good faith effort.
Remember, the Newswire article notes that Wellgistics Health is accelerating its digital health expansion by acquiring a proprietary Samsung Galaxy Watch monitoring program - a clear sign that the market is moving toward owning the device stack.
Future outlook: How the market will adapt
Even with a 65% revenue hit looming, the RPM space will not collapse. Instead, we will see a reshaping of business models. Providers that can pivot to an in-house model will likely capture a larger share of the $66.33 billion market projected for 2031, as highlighted by MarketsandMarkets. The shift will also accelerate innovation in low-cost wearables and AI-driven analytics, because companies will need to offset higher operational costs.
Key trends to watch:
- Hybrid models. Some firms will keep a small third-party pool for niche devices while owning the core platform.
- Bundled reimbursement. Negotiations with Medicare may evolve to include device costs within chronic-care management payments.
- Increased patient-owned data. As patients demand more control, platforms will need to support data export and consent management.
- Regulatory harmonisation. Australian and US regulators may align on standards, making cross-border device approvals smoother.
For providers, the takeaway is clear: adapt now or face a steep revenue decline. The three moves outlined earlier - audit, in-house roadmap, regulator engagement - are the scaffolding for a resilient RPM operation that can thrive under the new CMS landscape.
Frequently Asked Questions
Q: What exactly does the CMS third-party vendor ban prohibit?
A: The proposal would stop Medicare from paying for remote monitoring services that are delivered by an outsourced vendor rather than the clinician or provider directly. Any billing tied to a third-party device management contract could be denied.
Q: How quickly do I need to move to an in-house solution?
A: CMS expects providers to be compliant by the start of the 2025 calendar year. Starting the audit and roadmap now gives you a 12-month window to transition without disrupting patient care.
Q: Will the ban affect private health insurers?
A: The CMS rule applies only to Medicare. Private insurers may still reimburse third-party RPM services, but many will follow Medicare’s lead to avoid administrative complexity.
Q: Are there any exemptions for small practices?
A: CMS has hinted at possible pilot exemptions for practices with fewer than 100 Medicare patients, but providers must apply and demonstrate robust compliance controls.
Q: How does this change impact chronic-care management (CCM) billing?
A: CCM billing remains separate, but many practices bundle RPM with CCM. If RPM is denied, the bundled claim may be rejected, so it’s vital to split billing streams and ensure each meets CMS criteria.
